| MAGEA10c796 T | Autologous MAGE-A10-specific HLA-A2-restricted TCR c796 gene-engineered lymphocytes |
| MAG-EPA | Eicosapentaenoic acid monoacylglyceride |
| MAI R1530 | Mitosis-angiogenesis inhibitor R1530 |
| MAL cream | methyl-5-aminolevulinate hydrochloride cream |
| MAM-6 | MUC-1 antigen |
| mam-A DNA vaccine | mammaglobin-A DNA vaccine |
| MAP | MUTYH-associated polyposis |
| MASCT-I | Multiple TAA-loaded dendritic cell vaccine |
| MASL | Maackia amurensis seed lectin |
| MB | Methylene blue |
| MBEH | Monobenzone |
| MBL | Monoclonal B-cell lymphocytosis; Recombinant human mannose-binding lectin |
| MBV | Mixed bacteria vaccine |
| MBXD | Modified Banxia Xiexin decoction |
| MC1R | Melanocortin 1 receptor; Melanotropin receptor |
| MCC | Mycobacterial cell wall-DNA complex |
| MCNU | Ranimustine |
| MDMA | 3,4-methylenedioxymethamphetamine |
| MDMS | Methylene dimethane sulfonate |
| MDP EP-100 | Onvitrelin ucalontide |
| MDS | Myelodysplastic syndrome |
| MDX-010 | Ipilimumab; Yervoy |
| MDX-CTLA-4 | Ipilimumab |
| Me-4FDG | alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside |
| MeCCNU | Semustine |
| MEDI-507 | Siplizumab |
| MEDI-522 | Abegrin; Etaracizumab; Humanized monoclonal antibody MEDI-522 |
| M-EDTA | minocycline-EDTA |
| MEN2 | MEN2 syndrome; Multiple endocrine adenomatosis type 2; Multiple endocrine neoplasia type 2 syndrome |
| MEN2A | MEN2A syndrome; Multiple endocrine adenomatosis type 2A; Multiple endocrine neoplasia type 2A syndrome; Sipple syndrome |
| MEN2B | MEN2B syndrome; Multiple endocrine adenomatosis type 2B; Multiple endocrine neoplasia type 2B syndrome |
| MEPACT | Mifamurtide; Muramyl tripeptide phosphatidylethanolamine |
| MER | Methanol extraction residue of BCG |
| mesothelin-specific CAR-engineered PBLs | Mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes |
| MFS | Metastasis-free survival |
| MGBG | Mitoguazone |
| MGCD0103 | Mocetinostat |
| MGE | Muscadine grape extract |
| MGPT | Multigene panel test; Multigene test |
| MGUS | Monoclonal gammopathy of undetermined significance |
| MHP VAC | Melanoma helper peptide vaccine |
| MHT | Menopausal hormone therapy |
| MIBG | Iobenguane |
| miRNA | microRNA |
| MITC | Mitomycin |
| MK-0646 | anti-IGF1R recombinant monoclonal antibody MK-0646 |
| MLN1202 | anti-CCR2 monoclonal antibody MLN1202 |
| MLN518 | Tandutinib |
| MLPA | Multiplex ligation-dependent probe amplification |
| MLT | Therapeutic melatonin |
| ΜM | Micromole |
| MMDT | Maekmoondong-tang |
| MMF | Mycophenolate mofetil |
| MMMT | Malignant mixed Müllerian tumor |
| MMPR | Methylmercaptopurine riboside |
| M-M-R II | Measles/mumps/rubella vaccine |
| MNA-D | Micro needle array-doxorubicin |
| MnSOD-PL | MnSOD-plasmid liposomes |
| MNTX | Methylnaltrexone |
| Mo | Molybdenum |
| MOA | Mechanism of action |
| MOAB 105AD7 | Monoclonal antibody 105AD7 anti-idiotype vaccine |
| MoAb 11D10 | Monoclonal antibody 11D10 |
| MOAB 14G2A | Monoclonal antibody 14G2A |
| MOAB 17-1A | Edrecolomab |
| MOAB 1D10 | Apolizumab |
| MoAb 216 | Human monoclonal antibody 216 |
| MOAB 2C4 | Pertuzumab |
| MOAB 3F8 | Monoclonal antibody 3F8 |
| MOAB 3H1 | Monoclonal antibody 3H1 anti-idiotype vaccine |
| MOAB 4B5 | Monoclonal antibody 4B5 anti-idiotype vaccine |
| MOAB A27.15 | Monoclonal antibody A27.15 |
| MOAB A33 | Monoclonal antibody A33 |
| MOAB ABX-CBL | Gavilimomab |
| MoAb ABX-EGF | Panitumumab |
| MOAB anti-B1 | Tositumomab |
| MOAB anti-Tac | Daclizumab |
| MOAB B43.13 | Oregovomab |
| MOAB C225 | Cetuximab |
| MOAB CAL | Monoclonal antibody CAL |
| MOAB CC49 | Monoclonal antibody CC49 |
| MOAB CC49-deltaCH2 | Monoclonal antibody CC49-delta CH2 |
| MOAB Ch14.18 | Dinutuximab |
| MOAB CHIR-12.12 | Lucatumumab |
| MOAB E2.3 | Monoclonal antibody E2.3 |
| MOAB G250 | Girentuximab |
| MOAB hA20 | Veltuzumab |
| MOAB HeFi-1 | Monoclonal antibody HeFi-1 |
| MoAB HER2 | Trastuzumab |
| MOAB Hu3S193 | Monoclonal antibody Hu3S193 |
| MOAB HuAFP31 | Monoclonal antibody HuAFP31 |
| MOAB HuG1-M195 | Lintuzumab |
| MOAB HuPAM4 | Monoclonal antibody HuPAM4 |
| MOAB IDEC-114 | Galiximab |
| MOAB L6 | Monoclonal antibody L6 |
| MOAB Lym-1 | Monoclonal antibody Lym-1 |
| MOAB Me1-14 F(ab')2 | Monoclonal antibody Me1-14 F(ab')2 |
| MOAB Mik-beta-1 | Monoclonal antibody Mik-beta-1 |
| MOAB OKT3 | muromonab-CD3 |
| MOAB R24 | Monoclonal antibody R24 |
| moAb VX15/2503 | Pepinemab |
| MONO dgA RFB4 | Monoclonal antibody Mono-dgA-RFB4 |
| MOPP | MOPP regimen |
| MORAb-009 | Amatuximab; Anti-mesothelin monoclonal antibody MORAb-009 |
| MORPH | Morphine sulfate |
| mouse PSMA DNA | Mouse prostate-specific membrane antigen plasmid DNA vaccine |
| MOXI | Moxifloxacin hydrochloride |
| MP-3549.1 | Pegylated liposomal docetaxel prodrug MNK-010 |
| MP470 | Amuvatinib |
| MPA | Medroxyprogesterone acetate; Mycophenolic acid |
| MPB | VMP regimen |
| MPC | Mesenchymal stem cells |
| MPL | Monophosphoryl lipid A |
| MPNST | Malignant peripheral nerve sheath tumor |
| MPO | Leridistim |
| MR | Mitotic rate |
| MRA | Magnetic resonance angiography; Tocilizumab |
| MRCP | Magnetic resonance cholangiopancreatography |
| MRD | Measurable residual disease; Minimal residual disease |
| MRI | Nuclear magnetic resonance imaging |
| MRL | Magnetic resonance lymphangiography |
| mRNA | Messenger RNA |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| MRSI | 1H-nuclear magnetic resonance spectroscopic imaging; Proton magnetic resonance spectroscopic imaging |
| MSA | Mesna |
| MSC | Methylselenocysteine |
| MSCs/IL-12M | IL-12-expressing mesenchymal stem cell vaccine GX-051 |
| MSI | Microsatellite instability |
| MSKE | Muscadine grape skin extract |
| MSSE | Ferguson-Smith syndrome; Multiple self-healing squamous epithelioma |
| MTA | Pemetrexed disodium |
| MTD | Maximum tolerated dose |
| MTH | Plicamycin |
| mTHPC | Temoporfin |
| MTL-CEBPA | CEBPA-targeting saRNA MTL-CEBPA liposome |
| mTOR | Mammalian target of rapamycin; Mechanistic target of rapamycin |
| MTS | Muir-Torre syndrome |
| MTX | Methotrexate sodium; Trexall; Xatmep |
| MTX-ATMP | Methotrexate-encapsulating autologous tumor-derived microparticles |
| MTX-e TI | Methotrexate-e therapeutic implant |
| MUC1-KLH VAC | MUC1-KLH conjugate vaccine |
| MULTI-EP MP VAC | Multi-epitope melanoma peptide vaccine |
| multi-TAA-specific T cells | Donor-derived WT1/PRAME/NY-ESO-1/survivin-specific T-lymphocytes |
| MULTIVIT | Multivitamin |
| MUSE | Medicated urethral system for erection |
| MuSK-CAART | Autologous MuSK-CD3z/4-1BB-expressing chimeric autoantibody receptor T cells MuSK-CAART |
| MVA brachyury-TRICOM | Brachyury-expressing modified vaccinia Ankara-TRICOM vaccine |
| MVAC | MVAC regimen |
| MVA-MUC1-IL2 | Mesmulogene ancovacivec |
| MVAp53 vaccine | Modified vaccinia virus ankara vaccine expressing p53 |
| MV-CEA | Carcinoembryonic antigen-expressing measles virus |
| MV-NIS | Oncolytic measles virus encoding thyroidal sodium iodide symporter |
| MVP-S | maveropepimut-S |
| MZL | Marginal zone B-cell lymphoma; Marginal zone lymphoma |
| MZP | m-azidopyrimethamine |
| MZRW | Ma zi ren wan |